The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Octreotide Alone or With Prednisone in Patients With Advanced Thymoma and Thymic Carcinoma: An Eastern Cooperative Oncology Group Phase II Trial
Abstract
Purpose: To determine the objective response rate, duration of remission and toxicity of octreotide alone or with the later addition of prednisone in patients with unresectable, advanced thymic malignancies in whom the pretreatment octreotide scan was positive. Patients and Methods: Forty-two patients with advanced thymoma or thymic carcinoma were entered onto the trial, of whom 38 were fully assessable (one patient had inconclusive histology; three patients had negative octreotide scan). Patients received octreotide 0.5 mg subcutaneously tid. At 2 months, patients were evaluated. Responding patients continued to receive octreotide alone; patients with progressive disease were removed from the study. All others received prednisone 0.6 mg/kg orally qid for a maximum of 1 year. Results: Two complete (5.3%) and 10 partial responses (25%) were observed (four partial responses with octreotide alone; the remainder with octreotide plus prednisone). None of the six patients without pure thymoma responded. The 1- and 2-year survival rates were 86.6% and 75.7%, respectively. Patients with an Eastern Cooperative Oncology Group performance status of 0 lived significantly longer than did those with a performance status of 1 (P = .031). Conclusion: Octreotide alone has modest activity in patients with octreotide scan–positive thymoma. Prednisone improves the overall response rate but is associated with increased toxicity. Additional studies with the agent are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
Cited by
The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes
Marx, A., Chan, J. K. C., Coindre, J.-M., Detterbeck, F., Girard, N., Harris, N. L., Jaffe, E. S., Kurrer, M. O., Marom, E. M., Moreira, A. L., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000654 · Cited by 603
The Integrated Genomic Landscape of Thymic Epithelial Tumors
Radovich, M., Pickering, C. R., Felau, I., Ha, G., Zhang, H., Jo, H., Hoadley, K. A., Anur, P., Zhang, J., McLellan, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.003 · Cited by 381
Self-citationThe Management of Thymoma: A Systematic Review and Practice Guideline
Falkson, C. B., Bezjak, A., Darling, G., Gregg, R., Malthaner, R., Maziak, D. E., Yu, E., Smith, C. A., McNair, S., Ung, Y. C., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a4b8e0 · Cited by 283
Metadata
- Authors
- Loehrer, P. J., Wang, W., Johnson, D. H., & Ettinger, D. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-01-15
- Volume
- 22
- Issue
- 2
- Pages
- 293-299
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2167601464
- Cited by
- 208
- References
- 1
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Octreotide Alone or With Prednisone in Patients With Advanced Thymoma and Thymic Carcinoma: An Eastern Cooperative Oncology Group Phase II Trial. https://app.cochat.ai/papers/10.1200/jco.2004.02.047
- The paper
- Loehrer, P. J., Wang, W., Johnson, D. H., & Ettinger, D. S. (2004). Octreotide Alone or With Prednisone in Patients With Advanced Thymoma and Thymic Carcinoma: An Eastern Cooperative Oncology Group Phase II Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.02.047
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.